Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Dupilumab

Aliases
Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT], Dupilumab Dose 1, Dupilumab Dose 2, Dupilumab for MAD (12 other aliases)
Name
Dupixent
FDA Approved
Yes

110 clinical trials

1 organization

1 drug

59 indications

1 document

Indication
Cold Urticaria
Indication
Atopic Dermatitis
Indication
Chronic Obstructive Pulmonary Disease
Indication
Eosinophilic Gastritis
Indication
Eosinophilic Duodenitis
Indication
Eosinophilic Gastrointestinal Disease
Indication
Asthma
Indication
Prurigo Nodularis
Indication
Keratoconjunctivitis
Indication
Chronic Spontaneous Urticaria
Indication
Allergic Fungal Rhinosinusitis
Indication
Pruritus
Indication
Chronic Rhinosinusitis
Indication
Chronic Rhinosinusitis Without Nasal Polyps
Indication
Sinusitis
Indication
sinusitis
Indication
Respiratory Disorder
Indication
Healthy Participants
Indication
Peanut Allergy
Indication
Chronic Rhinosinusitis With Nasal Polyposis
Indication
Ulcerative colitis
Indication
Wheezing
Indication
Healthy Control Participants
Indication
Atopic dermatitis
Indication
Dermatitis
Indication
Atopic
Indication
Eosinophilic Esophagitis (EoE)
Indication
Healthy Volunteer
Indication
Eosinophilic Esophagitis
Indication
Allergy
Indication
Eczema
Indication
Olfactory Disorder
Indication
Dermal Hypersensitivity Reaction
Indication
EoE
Indication
Nummular Eczema
Indication
Contact Dermatitis
Indication
Metastatic Non-small Cell Lung Cancer
Indication
COVID-19
Indication
Alopecia Areata
Indication
Nasal Polyps
Indication
Staphylococcus aureus
Indication
Allergies
Indication
Chronic Hand Eczema
Indication
Skin Diseases
Indication
Hypersensitivity
Indication
Food Allergy
Indication
Food
Indication
Peanut Hypersensitivity
Indication
Cholinergic Urticaria
Indication
Netherton Syndrome
Indication
Eosinophilic Gastroenteritis
Indication
Keloid
Indication
Aspirin-induced
Indication
Aspirin-Exacerbated Respiratory Disease
Indication
Aspirin-Sensitive Asthma with Nasal Polyps
Indication
Pathophysiology
Indication
Sleep Disturbance
Indication
Psoriasis
Drug
dupilumab
Indication
NSCLC
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Study of Dupilumab in Patients With Chronic Inducible Cold Urticaria Who Remain Symptomatic Despite the Use of H1-antihistamine Treatment
Status: Completed, Estimated PCD: 2023-02-02
Clinical trial
French Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis.
Status: Recruiting, Estimated PCD: 2027-11-29
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation
Status: Active (not recruiting), Estimated PCD: 2024-02-28
Clinical trial
A Phase 2/3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis
Status: Recruiting, Estimated PCD: 2027-08-19
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Dupilumab Compared to Placebo in Japanese Patients With Atopic Dermatitis Aged 6 Months to
Status: Completed, Estimated PCD: 2021-12-14
Clinical trial
A Randomized Double-blind Placebo-controlled Parallel Group Study Assessing the Efficacy and Safety of Dupilumab in Patients With Allergic Fungal Rhinosinusitis (AFRS)
Status: Active (not recruiting), Estimated PCD: 2024-12-10
Clinical trial
PRospEctiVe charactErization of Asthma Patients Treated With DupilumAb in reaL World Setting
Status: Recruiting, Estimated PCD: 2026-12-21
Clinical trial
A Multi-center, Single-arm Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Male and Female Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU)
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Prospective Observational Study of Patients Receiving Dupilumab for Prurigo Nodularis
Status: Recruiting, Estimated PCD: 2031-06-23
Clinical trial
A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Prospective, Non-interventional Observational Study to Characterize Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine
Status: Recruiting, Estimated PCD: 2025-04-23
Clinical trial
Master Protocol of Two Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Studies to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Chronic Pruritus of Unknown Origin (CPUO)
Status: Recruiting, Estimated PCD: 2025-03-21
Clinical trial
Open-label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Chinese Patients With Moderate to Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2024-01-25
Clinical trial
A Single-arm, 52 Weeks, Phase 4 Study to Assess the Efficacy and Safety of Dupilumab in Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) Who Are Not Adequately Controlled With Existing Therapies
Status: Completed, Estimated PCD: 2022-12-21
Clinical trial
A Phase 2a, Multicenter, Proof-of-Concept Clinical Trial to Evaluate Efficacy and Safety of BSI-045B mAb Injection as Monotherapy or Add-on Therapy With Dupilumab in Patients With Moderate to Severe Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2024-11-18
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Chinese Adult Patients With Moderate-to-severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2020-02-14
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation
Status: Completed, Estimated PCD: 2023-02-08
Clinical trial
A Prospective Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis
Status: Active (not recruiting), Estimated PCD: 2027-03-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Uncontrolled, Chronic Rhinosinusitis Without Nasal Polyposis (CRSsNP)
Status: Completed, Estimated PCD: 2023-11-14
Clinical trial
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma
Status: Recruiting, Estimated PCD: 2029-10-31
Clinical trial
A Phase 3b Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2020-08-27
Clinical trial
A Phase 3b/4 Randomized, Open-label, Efficacy Assessor Blinded Study, Comparing the Safety and Assessor Blinded Efficacy of Upadacitinib to Dupilumab in Subjects With Moderate to Severe Atopic Dermatitis (Level-Up)
Status: Active (not recruiting), Estimated PCD: 2024-03-19
Clinical trial
Open-label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Chinese Pediatric Patients With Moderate-to-severe Atopic Dermatitis
Status: Active (not recruiting), Estimated PCD: 2023-12-22
Clinical trial
A Phase 1 FIH, Randomized, Double Blind, Placebo Controlled, SAD/MAD Study to Assess Safety, Tolerability and PK in Healthy Participants and in Atopic Dermatitis Patients
Status: Recruiting, Estimated PCD: 2024-09-27
Clinical trial
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study in Pediatric Subjects With Peanut Allergy to Evaluate the Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
Status: Completed, Estimated PCD: 2020-10-16
Clinical trial
A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizumab in Severe Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) and Comorbid Asthma Patients
Status: Recruiting, Estimated PCD: 2025-01-15
Clinical trial
Observational Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) Treated With Dupilumab in France
Status: Recruiting, Estimated PCD: 2026-04-28
Clinical trial
A Multicenter Open-label Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
Status: Recruiting, Estimated PCD: 2027-10-28
Clinical trial
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Parallel-group Study to Evaluate the Efficacy and Safety of Dupilumab Therapy in Patients With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype
Status: Recruiting, Estimated PCD: 2024-06-26
Clinical trial
Master Protocol of Three Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite the Use of H1 Antihistamine Treatment in Patients naïve to Omalizumab and in Patients Who Are Intolerant or Incomplete Responders to Omalizumab
Status: Active (not recruiting), Estimated PCD: 2024-08-22
Clinical trial
A Prospective Observational Study of Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Receiving Dupilumab
Status: Recruiting, Estimated PCD: 2026-01-31
Clinical trial
A Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab, in Chinese Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) on a Background Therapy With Intranasal Corticosteroids
Status: Active (not recruiting), Estimated PCD: 2024-10-02
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Longterm Safety of Dupilumab in Children 2 to <6 Years of Age With Uncontrolled Asthma and/or Recurrent Severe Asthmatic Wheeze
Status: Recruiting, Estimated PCD: 2028-12-21
Clinical trial
A Randomized, Open-label, Parallel Design, Single Dose Study to Compare the Pharmacokinetics of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults
Status: Completed, Estimated PCD: 2021-09-24
Clinical trial
A Randomized, Open-label, Parallel Design Study of the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products After Administration of Single Subcutaneous Doses
Status: Completed, Estimated PCD: 2015-03-30
Clinical trial
A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable
Status: Completed, Estimated PCD: 2021-11-12
Clinical trial
601-0018
Status:
Clinical trial
A Multi-center, Exploratory Study to Assess Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
Status: Completed, Estimated PCD: 2022-06-30
Clinical trial
A Randomized Double-blind, Placebo-controlled Study Evaluating the Effect of Dupilumab on Sleep in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
Status: Completed, Estimated PCD: 2021-10-06
Clinical trial
A Randomized, Open-label, Parallel Design Study of the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products After Administration of Single Subcutaneous Doses
Status: Completed, Estimated PCD: 2015-01-17
Clinical trial
A Phase 2b, Multicenter, Randomized, Placebo- and Active-comparator-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Participants With Moderate to Severe Atopic Dermatitis
Status: Terminated, Estimated PCD: 2022-02-02
Clinical trial
A Randomized, Double Blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma
Status: Completed, Estimated PCD: 2022-05-21
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis
Status: Active (not recruiting), Estimated PCD: 2022-06-02
Clinical trial
Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma
Status: Completed, Estimated PCD: 2023-06-26
Clinical trial
Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial
Status: Completed, Estimated PCD: 2022-02-18
Clinical trial
One Year Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Pediatric Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study
Status: Active (not recruiting), Estimated PCD: 2025-03-31
Clinical trial
A Randomized, Double Blind, Placebo-controlled, Multi-center, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Prurigo Nodularis Who Are Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable
Status: Completed, Estimated PCD: 2021-08-30
Clinical trial
A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
Status: Completed, Estimated PCD: 2021-09-09
Clinical trial
Open-label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Pediatric Patients With Moderate to Severe Atopic Dermatitis
Status: Completed, Estimated PCD: 2022-09-07
Clinical trial
An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to <18 Years of Age With Atopic Dermatitis
Status: Active (not recruiting), Estimated PCD: 2026-08-19
Clinical trial
An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials
Status: Completed, Estimated PCD: 2022-06-27
Clinical trial
A Prospective Observational Study of Patients Receiving DUPIXENT® for Atopic Dermatitis
Status: Active (not recruiting), Estimated PCD: 2027-03-30
Clinical trial
Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Mechanistic Trial of Dupilumab in Adults With House Dust Mite-associated Asthma Using an Aeroallergen Challenge Chamber
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis
Status: Recruiting, Estimated PCD: 2024-04-30
Clinical trial
Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping
Status: Recruiting, Estimated PCD: 2027-06-30
Clinical trial
The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients
Status: Completed, Estimated PCD: 2022-12-15
Clinical trial
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis (ADRN-12)
Status: Recruiting, Estimated PCD: 2025-05-07
Clinical trial
The 'Real World' Olfactory Outcomes Treating Nasal Polyposis With Dupilumab
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Real Life Experience Survey of Dupilumab in the Netherlands
Status: Completed, Estimated PCD: 2022-10-30
Clinical trial
The Immunologic Effects of Dupilumab in the Treatment of Dermal Hypersensitivity Reaction
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Randomized, 52-week Treatment Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
Dupilumab for Eosinophilic Esophagitis With Severe Strictures (DESTRICT Study)
Status: Not yet recruiting, Estimated PCD: 2025-11-01
Clinical trial
The Effects of Dupilumab on Allergic Contact Dermatitis
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion in the Real Life Severe Asthma Patients
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
An Investigator-initiated, Multi-center, Randomized, Double-blind, Placebo Controlled Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema
Status: Recruiting, Estimated PCD: 2026-01-31
Clinical trial
Anti-IL4/IL13 Therapy With Dupilumab for Prevention of Refractory Chronic Rhinosinusitis After Endoscopic Sinus Surgery for CRSwNP
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
IL-4 & Insulin Resistance in Patients With Atopic Dermatitis
Status: Completed, Estimated PCD: 2024-02-23
Clinical trial
A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy of Dupixent in Adults With Refractory Post-Burn Pruritus in an Ambulatory Clinic
Status: Not yet recruiting, Estimated PCD: 2026-01-31
Clinical trial
A Phase 1b/2 Trial of Dupilumab Given in Conjunction With PD-1 or PD-L1 Blockade in the Treatment of Relapsed/Refractory Metastatic NSCLC
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Effect of Dupilumab on Nasal Epithelial Barrier Function in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - an Exploratory Pilot Study
Status: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Randomized, Placebo-controlled, Parallel Group Study Designed to Assess the Change in Mucociliary Clearance After 12 Weeks of Treatment With Dupilumab in Patients With Moderate to Severe Asthma
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Safety and Efficacy of the Treatment of Hospitalized Patients With COVID 19 Infection With an Inhibitor of IL-4 and IL-13 Signaling: A Phase IIa Trial
Status: Completed, Estimated PCD: 2023-04-18
Clinical trial
Viral Infection in Asthma (VIA) Study
Status: Recruiting, Estimated PCD: 2025-05-31
Clinical trial
Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis: a Non-inferiority Randomized Trial
Status: Recruiting, Estimated PCD: 2026-03-08
Clinical trial
Dupilumab in the Treatment of Pediatric Alopecia Areata
Status: Not yet recruiting, Estimated PCD: 2028-04-30
Clinical trial
Ethnic Differences in Mechanisms of Action of Dupilumab
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Interleukin-4Ralpha Blockade by Dupilumab Decreases Staphylococcus Aureus Colonization and Increases Microbial Diversity in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Dupilumab De-escalation in Pediatric Atopic Dermatitis: A Pilot Trial
Status: Recruiting, Estimated PCD: 2026-04-01
Clinical trial
Effects of IL-4R-alpha Inhibition (Dupixent) Inhibition On The Respiratory Microbiome And Immunologic Correlates In Patients With Severe Asthma
Status: Completed, Estimated PCD: 2023-06-29
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab and Milk Oral Immunotherapy for the Treatment of Patients With Cow's Milk Allergy
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
DUPECZEMAIN : Double Blind Placebo-controlled Randomized Multicenter Study Assessing the Efficacy and Safety of Dupilumab in Moderate to Severe Chronic Hands Eczema Refractory to Highly Potent Topical Corticosteroids
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders: a Single-Site Pilot Study
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Mechanisms of Smell Improvement With Dupilumab
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Phase 2 Randomized Controlled Trial Using Biologics to Improve Multi OIT Outcomes
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
'Mind and Skin': A Prospective Cohort Study Evaluating the Impact of Inflammation, Itch and Sleep Disturbance on the Brain, Mental Health and Cognition, in Patients With Severe Atopy
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Proof of Concept, Multicenter, 16-week Treatment Study With a 16 Week Follow-up Period to Assess the Efficacy and Safety of Dupilumab (Anti-IL4Ra) in Adult Patients With Cholinergic Urticaria Despite H1-antihistamine Treatment
Status: Completed, Estimated PCD: 2023-02-28
Clinical trial
A Randomized Double-blinded Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy of Dupilumab (Anti-IL4a) in Subjects With Eosinophilic Gastritis
Status: Active (not recruiting), Estimated PCD: 2024-03-10
Clinical trial
Effect of IL-4RαR576 Polymorphism on Response to Dupilumab in Asthma, a Genotype-stratified, Randomized, Placebo- Controlled Trial
Status: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus: an Open-Label, Single-Arm, Exploratory Study
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
An Open-label Proof of Concept Study Regarding the Efficacy and Safety of Dupilumab in the Treatment of Keloids
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
DUPI REDUCE Trial (DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema): a Multicenter, Low-intervention, Non-inferiority Randomized Controlled Trial, Embedded in the TREAT NL Registry
Status: Recruiting, Estimated PCD: 2024-10-15
Clinical trial
Dupilumab in the Treatment of Alopecia Areata Patients With an Atopic Background and/or High IgE
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Defining Reversal of Keloid Lesions by Th2 Targeting With Dupilumab Treatment
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents (PANDA) (CAUSE-01)
Status: Recruiting, Estimated PCD: 2025-08-30
Clinical trial
Early Changes in Type 2 Inflammatory Cytokines, Respiratory Oscillometry, and Sinonasal Microbiome With Dupilumab Treatment for Chronic Rhinosinusitis With Nasal Polyps
Status: Withdrawn, Estimated PCD: 2026-06-01
Clinical trial
Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease: MARINER
Status: Recruiting, Estimated PCD: 2026-04-30
Clinical trial
Effectiveness of Dupilumab in the Treatment of Severe Uncontrolled CRSwNP: a Multicentre Observational Real-life Study (DUPIREAL)
Status: Active (not recruiting), Estimated PCD: 2022-10-01
Clinical trial
A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects With Moderate to Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP)
Status: Recruiting, Estimated PCD: 2025-08-22
Clinical trial
On the Origin of Immunoglobulin E's: Elucidating the Immunological Mechanisms Underlying Mucosal IgE Responses in type2 Disease
Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
The Utility of Functionally Relevant Signature Genes in Assessing the Clinical Outcomes of Dupilumab Treatment
Status: Completed, Estimated PCD: 2022-11-18
Clinical trial
Molecular Signatures of Cutaneous Dupilumab Response
Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
Status: Not yet recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 1/2 Study of Combined Treatment With Dupilumab (Anti-IL-4Ra) and Cemiplimab (Anti-PD-1) in Patients With Early-stage, Resectable NSCLC
Status: Recruiting, Estimated PCD: 2027-03-01
Clinical trial
A Phase 4, Randomized, Multicenter, Double-blind, Parallel-group, 24 Weeks, Placebo-controlled Study Followed by 104 Weeks Open-label to Assess Dupilumab Efficacy on Esophageal Function and Remodeling in Adult Participants With Eosinophilic Esophagitis (EoE)
Status: Recruiting, Estimated PCD: 2025-12-09
Clinical trial
Systematic Profiling of Anti-cytokine Signatures in the Treatment of Chronic Inflammatory Skin Disorders
Status: Recruiting, Estimated PCD: 2027-12-31
Clinical trial
Prospective, Observational, Longitudinal Study in Paediatric Patients With AD, Treated With Dupilumab in Spain
Status: Not yet recruiting, Estimated PCD: 2026-09-30
Clinical trial
Biologics and Blistering - Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Through Suction Blistering
Status: Recruiting, Estimated PCD: 2027-01-01
Document
DailyMed Label: Dupixent
Organization
Sanofi-Aventis U.S. LLC